United States subject matter eligibilityproducts of nature

Myriad Genetics (Association for Molecular Pathology v)

569 US 576 (2013)

JurisdictionUnited States

CourtSupreme Court of the United States

Year2013

StatusBinding authority

Key Principle

Naturally occurring DNA segments are products of nature and are not patent-eligible under 35 USC §101; synthetically created complementary DNA (cDNA) is patent-eligible.

Area of Law

Related Cases

Warner Chappell Music Inc v Nealy 601 U.S. 366 (2024)

Vidal v Elster 602 U.S. 286 (2024)

Andy Warhol Foundation for the Visual Arts Inc v Goldsmith 598 U.S. 508 (2023)

Ask CommonBench about this case

Get a detailed analysis of Myriad Genetics (Association for Molecular Pathology v) and how it applies to your situation.

Explain Myriad Genetics (Association f...